Regeneron’s earnings boosted by more than doubling of U.S. sales of blockbuster eye drug Eylea

Regeneron’s earnings boosted by more than doubling of U.S. sales of blockbuster eye drug Eylea




Regeneron Pharmaceuticals Inc.’s stock rose 4.9% Tuesday to put it on track for its biggest one-day gain in almost two years, after the company posted better-than-expected fourth-quarter earnings, boosted by strong demand for a new formulation of its blockbuster eye drug Eylea.



Source link

Tagged:

Related News

Popular News

Categories Collection

Recent News